Stock Scorecard



Stock Summary for Repligen Corp (RGEN) - $143.60 as of 7/31/2026 3:37:46 PM EST

Total Score

11 out of 30

Safety Score

51 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for RGEN

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for RGEN

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for RGEN

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for RGEN

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for RGEN (51 out of 100)

Stock Price Rating (Max of 10) 10
Historical Stock Price Rating (Max of 10) 10
Stock Price Trend (Max of 10) 2
Book Value (Max of 10) 8
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 2
Trading Volume (Max of 10) 9
Price to Earnings (Max of 10) 1
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for RGEN

Why Repligen (RGEN) Is Up 6.9% After Mixed Q2 2026 Results With Higher Revenue And Lower EPS 8/1/2026 9:10:00 AM
Repligen Corp (RGEN) Institutional Confidence 8/1/2026 8:10:00 AM
Vanguard Capital Management reports 5% Repligen (RGEN) stake in Schedule 13G 7/31/2026 2:46:00 PM
Repligen (RGEN) Stock Faces A Margin Puzzle After Revenue Growth 7/30/2026 7:39:00 PM
Repligen (NASDAQ:RGEN) Combines Strong Growth with a Promising Technical Breakout Setup 7/30/2026 12:14:00 PM
Repligen Corp Q2 2026: Revenue $204.1M, EPS $0.09— 10-Q Summary 7/30/2026 4:09:00 AM
BioLife $1.5B buyout to expand Repligen Corporation (NASDAQ: RGEN) platform 7/29/2026 8:14:00 PM
Why Repligen (RGEN) Stock Is Up Today 7/29/2026 3:14:00 PM
Repligen Offers Differentiated Solutions as a Leading Bioprocessing Supplier 7/29/2026 12:40:00 PM
Canaccord reiterates Hold on Repligen stock, keeps $145 target 7/29/2026 11:40:00 AM

Financial Details for RGEN

Company Overview

Ticker RGEN
Company Name Repligen Corp
Country USA
Description Repligen Corporation develops and markets bioprocessing systems and technologies for use in the biologic drug manufacturing process in North America, Europe, Asia Pacific, and internationally. The company is headquartered in Waltham, Massachusetts.
Sector Name HEALTHCARE
Industry Name MEDICAL INSTRUMENTS & SUPPLIES
Most Recent Quarter 6/30/2026
Next Earnings Date N/A

Stock Price History

Last Day Price 143.60
Price 4 Years Ago 169.31
Last Day Price Updated 7/31/2026 3:37:46 PM EST
Last Day Volume 1,042,805
Average Daily Volume 1,270,762
52-Week High 175.77
52-Week Low 100.99
Last Price to 52 Week Low 42.19%

Valuation Measures

Trailing PE 156.09
Industry PE 60.45
Sector PE 58.81
5-Year Average PE 104.75
Free Cash Flow Ratio 11.58
Industry Free Cash Flow Ratio 25.41
Sector Free Cash Flow Ratio 31.51
Current Ratio Most Recent Quarter 9.05
Total Cash Per Share 12.40
Book Value Per Share Most Recent Quarter 37.33
Price to Book Ratio 3.28
Industry Price to Book Ratio 2.99
Sector Price to Book Ratio 9.48
Price to Sales Ratio Twelve Trailing Months 10.32
Industry Price to Sales Ratio Twelve Trailing Months 44.73
Sector Price to Sales Ratio Twelve Trailing Months 9.46
Analyst Buy Ratings 14
Analyst Strong Buy Ratings 4

Share Statistics

Total Shares Outstanding 56,436,000
Market Capitalization 8,104,209,600
Institutional Ownership 120.19%

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 2.68%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY -65.90%
Annual Earnings Growth 291.64%
Reported EPS 12 Trailing Months 0.92
Reported EPS Past Year 1.02
Reported EPS Prior Year 1.71
Net Income Twelve Trailing Months 41,539,000
Net Income Past Year 48,894,000
Net Income Prior Year -25,514,000
Quarterly Revenue Growth YOY 11.90%
5-Year Revenue Growth 15.05%
Operating Margin Twelve Trailing Months 9.31%

Balance Sheet

Total Cash Most Recent Quarter 606,783,000
Total Cash Past Year 566,021,000
Total Cash Prior Year 757,355,000
Net Cash Position Most Recent Quarter 60,198,000
Net Cash Position Past Year 23,808,000
Long Term Debt Past Year 542,213,000
Long Term Debt Prior Year 525,567,000
Total Debt Most Recent Quarter 546,585,000
Equity to Debt Ratio Past Year 0.80
Equity to Debt Ratio Most Recent Quarter 0.79
Total Stockholder Equity Past Year 2,106,129,000
Total Stockholder Equity Prior Year 1,972,718,000
Total Stockholder Equity Most Recent Quarter 2,112,032,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months 110,777,000
Free Cash Flow Per Share Twelve Trailing Months 1.96
Free Cash Flow Past Year 93,898,000
Free Cash Flow Prior Year 142,489,000

Options

Put/Call Ratio 0.09
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 0.00
MACD Signal 0.00
20-Day Bollinger Lower Band 0.00
20-Day Bollinger Middle Band 0.00
20-Day Bollinger Upper Band 0.00
Beta 1.06
RSI 0.00
50-Day SMA 0.00
150-Day SMA 146.22
200-Day SMA 152.28

System

Modified 8/1/2026 1:19:18 AM EST